However, another recent study, TAXYNERGY, failed to show a better response of AR-V7-mutated prostate cancers to taxanes: in fact, they observed a median PFS of 12 vs. 8.48 months for AR-V7-negative vs. AR-V7-positive tumors [239]. The gene discussed is AR; the disease is prostate carcinoma.